

**May 07, 2026**

**BSE Limited**

Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
Scrip Code: 524742

**National Stock Exchange of India Ltd.,**

Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

**Sub: Board meeting intimation**

This is to inform that a meeting of the Board of Directors of the Company will be held on Thursday, May 14, 2026, to consider and approve, *inter-alia*, the annual audited financial results of the Company for the year ended March 31, 2026 (both standalone & consolidated) and declaration of Interim Dividend, if any, for the FY 2025-26 and fixation of record date for determining the eligibility of shareholders.

This intimation is being given in compliance with the provisions of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As informed earlier vide our letter dated March 27, 2026, the trading window for dealing in the Company's scrips by the Designated Persons commenced on April 1, 2026 and will remain closed till May 16, 2026 (both days inclusive), in terms of the Company's Code of Conduct to regulate, monitor and report trading by insiders, read with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Kindly take the same on your records.

Sincerely Yours

**For Caplin Point Laboratories Limited**

**Venkatram G**  
**General Counsel & Company Secretary**  
**Membership No A23989**